Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers

Baze WB, Lvovsky E, Higabee GA, Levy HB, Hilmas DE (1979) Evaluation of a nuclease-resistant derivative of poly (I) poly (C) [Poly(ICLC)] as a radioprotective agent. Radiat Res 77: 276 Brunda MJ, Rosenbaum D (1984) Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 44: 597 Chedid L, Morin A (1982) Current status of muramyl peptides. In: Serrou B (ed) Current concepts in human immunology and cancer immunomodulation. Elsevier Biomedical Press BV, New York, p 535 Chirigos MA (1978) In vitro and in vivo studies with thymosin. In: Chirigos MA (ed) Immune modulation and control of neoplasia by adjuvant therapy. Raven Press, New York, p 305 Chirigos MA, Stylos WA (1980) Immunomodulatory effect of various molecular-weight-maleic anhydridedivinyl ethers and other agents in vivo. Cancer Res 40: 1967 Chirigos MA, Styles WA, Schultz RM, Fullen JR (1978) Chemical and biological adjuvants capable of potentiating tumor cell vaccine. Cancer Res 38: 1085 Chirigos MA, Papademetrious V, Bartocci A, Read E, Levy HB (1981) Immune response modifying activity in mice with polyinosinc: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose (poly ICLC). Int J Immunopharmacol 3: 329 Chirigos MA, Saito T, Talmadge JE (1984) The immunomodulatory activity of picibanil (OK-432). In: Hoshino T, Uchida A (eds) Excerpta Medica, Amsterdam, p 20 Devita VT, Oliverio VT, Miggia FM (1979) The drug development and clinical trials program of the division of cancer treatment, National Cancer Institute. Cancer Clin Trials 2: 195 Djeu JY, Heinbaugh JA, Holden HT, Herberman RB (1979) Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 122: 175 Fidler IJ, Poste G (1982) Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol 5: 161 Fidler IJ, Berendt M, Oldham RK (1982) The rationale for and design of a screening procedure for the assessment of biological response modifiers for cancer treatment. J Biol Resp Modif 1: 15 Goldin A, Johnson RK, Venditti JM (1980) Usefulness and limitation of murine tumor models for the identification of new antitumor agents. In: Mihich E, Eckhardt S (eds) Design of cancer chemotherapy: Experimental and clinical approaches. Karger, Switzerland, p 1 Kino T, Hashimoto S, Nakahara K, Gotoh T, Aoki H, Imanaka H (to be published) Inhibition of tumor metastasis by selective activation of natural killer cells with immunoactive peptides, FK-565 and FK-091. J Biol Res Modif Matter A (1979) The effects of muramyl dipeptide (MDP) in cell-mediated immunity. Cancer Immunol Immunother 6: 201 Mihich E, Fefer A (1983) Biological response modifiers subcommittee report. In: National Cancer Institute Monograph 63 (ed) US Government Printing Office, Washington DC Oldham RK (1982) Biological response modifiers program. J Biol Resp Modif 1: 81 Puccetti P, Santoni A, Riccardi C, Holden HT, Herberman, RB (1979) Activation of mouse macrophages by pyran copolymer and role in augmentation of natural killer activity. Int J Cancer 24: 819 Rose WC, Reed FC, Siminoff P, Bradner WT (1984) Immunotherapy of Madison 109 lung carcinoma and other murine tumors using lentinan. Cancer Res 44: 1368 Schabel FM Jr (1981) Laboratory methods for the detection and development of clinically useful anticancer drugs. In: Burchenal JH, Oettgen H (eds) Cancer: Achievements, challenges and prospects for the 1980s. Grune and Stratton, New York, p 11 Suga T, Shiio T, Maeda YY, Chihara G (1984) Antitumor activity of lentinan in marine syngeneic and autochthonous hosts and its suppressive effect on 3-methylcholanthrene-induced carcinogenesis. Cancer Res 44: 5132 Tahnadge JE (1984) Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin 2. J Biol Resp Modif 4: 18 Talmadge JE, Herberman RB (to be published) Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep Talmadge JE, Oldham RK, Fidler IJ (1984) Practical consideration for the establishment of a screening procedure for the assessment of biological response modifiers. J Biol Resp Modif 3: 88 Talmadge JE, Fidler IJ, Oldham RK (1984) The NCI preclinical screen of biological response modifiers. Behring Inst Mitt 74: 189 Talmadge JE, Uithoven KA, Lenz BF, Chirigos MA (1984) Immunomodulation and therapeutic characterization of thymosin fraction five. Cancer Immunol Immunother 18: 185 Talmadge JE, Lenz BE, Collins MS, Uithoven KA, Schneider MA, Adams IS, Pearson JW, Agee WJ, Fox RI, Oldham RK (1984) Tumor models to investigate the therapeutic efficiency of immunomodulators. Behring Inst Mitt 74: 219 Talmadge JE, Maluish AE, Collins M, Schneider M, Herberman RB, Oldham RK, Wiltrout RH (1984) Immunomodulation by MVE-2: a comprehensive study. J Biol Resp Modif 3: 634 Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Schlick E, Ruffman R, Wiltrout RH, Chirigos MA (1985) Immunomodulatory effects of poly ICLC in mice. Cancer Res 45: 1058 Talmadge JE, Adams J, Phillips H, Collins M, Lenz B, Schneider M, Chirigos M (1985) Immunotherapeutic potential of poly ICLC in murine tumor models. Cancer Res 45: 108 Talmadge JE, Fidler IJ, Oldham RK (1985) Screening for biological response modifiers: Methods and rationale. Martinus Nijhoffe, Boston Talmadge JE, Schneider M, Collins M, Phillips H, Herberman RB, Wiltrout RH (1985) Augmentation of NK cell activity in tissue-specific sites by liposomes incorporating MTP-PE. J Immunol 135: 1477 Talmadge JE, Dennis-Tait S, Schneider ME, Meeker A, Adams J, Ortaldo J, Wiltrout RH (1985) In vitro and in vivo stimulation on murine lymphocytes by human recombinant interleukin 2 (rIL-2). In: Hellmann K, Eccles SA (eds) Treatment of metastases: Problems and prospects. Taylor and Francis Philadelphia Talmadge JE, Lenz BE, Klabansky L, Simon R, Riggs C, Guo S, Oldham RK, Fidler IJ (to be published) Therapy of autochthonous skin cancers in mice with intravenously injected liposomes containing muramyl-tripeptide. Science Venditti JM (1983) The National Cancer Institute antitumor drug discovery program, current and future perspectives: A commentary. Cancer Treat Rep 67: 767 Venditti JM, Wesley RA, Plowman J (1984) Current NCI pre-clinical antitumor screening in vivo. In: Advances in pharmacology and chemotherapy. Academic Press, New York Wiltrout RH, Herberman RB, Zhang S, Chirigos MA, Ortaldo JR, Green KM, Talmadge JE (1985) Role of organ-associated NK cells in decreased formation of experimental metastases in lung and liver. J Immunol 134: 4267